OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - Q2 revenue of $29.2 million, increased 55$18.6 million - Paid down $4.5 million of principal on outstanding term loan during Q2 - Increased full year 2025 guidance to a revenue range between$104 million and $108 million and adjusted EBITDA range between$14.5 million and $17.5 million WALTHAM, Mass. – August 7, 2025 – OptimizeRx Corp. (the "Comp ...